Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

As the Trump administration makes cuts to federal health agencies, some Alzheimer's experts are worried about the impact on ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's ...

According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...

Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

Scientists say the map of a speck of a mouse's brain could be as transformative as the Human Genome Project. Here's what to ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and ...